Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Mar 16:12:632674.
doi: 10.3389/fendo.2021.632674. eCollection 2021.

Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study

Sigal Kaplan  1 , Rachel Levy-Toledano  2 , Miranda Davies  3   4 , Debabrata Roy  3   4 , Colin M Howles  5 , Amir Lass  5
Affiliations
Comparative Study

Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study

Sigal Kaplan et al. Front Endocrinol (Lausanne). .

Abstract

Background: Ovaleap® (follitropin alfa), a recombinant human follicle stimulating hormone, is a biosimilar medicinal product to Gonal-f® and is used for ovarian stimulation. The main objective of this study was to assess the safety and effectiveness of Ovaleap® compared to Gonal-f® in one treatment cycle in routine clinical practice.

Methods: Safety of Ovaleap® Follitropin alfa in Infertile women undergoing superovulation for Assisted reproductive technologies (SOFIA) was a prospective cohort study conducted in six European countries. Eligible patients were infertile women undergoing superovulation for assisted reproductive technology, who were administered Ovaleap® or Gonal-f® for ovarian stimulation and were naïve to follicle stimulating hormone treatment. The recruitment ratio was 1:1. The primary endpoint was incidence proportion of ovarian hyperstimulation syndrome (OHSS) and the secondary endpoint was OHSS severity (Grades I, II, III). The effect of risk factors or potential confounders on the odds ratio for OHSS incidence as well as treatment effect on OHSS incidence was explored using univariate logistic regression. Pregnancy and live birth rates were also assessed.

Results: A total of 408 women who were administered Ovaleap® and 409 women who were administered Gonal-f® were eligible for analysis. The incidence proportion of OHSS was 5.1% (95% CI: 3.4, 7.7) in the Ovaleap® cohort and 3.2% (95% CI: 1.9, 5.4) in the Gonal-f® cohort. This difference in OHSS incidence proportion between the two cohorts was not statistically significant neither before (p = 0.159) nor after univariate adjustment for each potential confounder (p > 0.05). The incidence proportion of OHSS severity grades was similar in the two treatment groups (3.4% versus 2.0% for Grade I, 1.2% versus 1.0% for Grade II, and 0.5% versus 0.2% for Grade III, in the Ovaleap® and Gonal-f® cohorts, respectively), without a significant statistical difference (p = 0.865, for each grade). Among patients who had embryo transfer, clinical pregnancy rates were 33% and 31% and live birth rates were 27% and 26%, in the two cohorts, respectively.

Conclusions: Findings from the SOFIA study indicate that the incidence proportions of OHSS and OHSS severity, as well as pregnancy and live birth rates, are similar between Ovaleap® and Gonal-f® treatments and corroborate the safety and effectiveness of Ovaleap® as a biosimilar to Gonal-f®.

Keywords: Gonal-f®; Ovaleap®; follitropin alfa; live birth rate; ovarian hyperstimulation syndrome; pregnancy outcome; pregnancy rate; safety.

PubMed Disclaimer

Conflict of interest statement

SK is an employee of Teva Pharmaceuticals Industries Ltd. RL-T is a consultant in RLT Media Consulting. RL-T was a consultant to Teva Pharmaceutical Industries Ltd. (and/or its affiliates), and then to Theramex at the time of study conduct. MD and DR are employees of the Drug Safety Research Unit (DSRU). The DSRU is an independent, academic research institution, and has received funds from Theramex for consulting on the study. CH and AL are consultants to Theramex.

Figures

Figure 1
Figure 1
Flow diagram of patient disposition: from enrollment to analysis and study completion. FSH, follicle stimulating hormone.
See this image and copyright information in PMC

References

    1. Practice Committee of the American Society for Reproductive Medicine . Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril (2016) 106(7):1634–47. 10.1016/j.fertnstert.2016.08.048 - DOI - PubMed
    1. Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol (2012) 10:32. 10.1186/1477-7827-10-32 - DOI - PMC - PubMed
    1. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update (2002) 8(6):559–77. 10.1093/humupd/8.6.559 - DOI - PubMed
    1. D’Angelo A, Amso NN, Hassan R. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Systematic Rev (2017) 5(5):Cd002811. 10.1002/14651858.CD002811.pub4 - DOI - PMC - PubMed
    1. Humaidan P, Nelson SM, Devroey P, Coddington CC, Schwartz LB, Gordon K, et al. . Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod (2016) 31(9):1997–2004. 10.1093/humrep/dew149 - DOI - PubMed

Publication types

MeSH terms

Substances